Skip to main content

Mini-Sentinel: Diabetic Ketoacidosis following Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, Sulfonylureas, Saxagliptin, and Sitagliptin Use: A Descriptive Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    saxagliptin
    sitagliptin
    sodium-glucose cotransporter-2 (SGLT-2) inhibitor
    sulfonylurea
    Health Outcome(s)
    diabetic ketoacidosis
    Description

    In this request we estimated the rate of diabetic ketoacidosis (DKA) among new users of Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas, saxagliptin, and sitagliptin in the Mini-Sentinel Distributed Database (MSDD). We distributed this request to 13 Data Partners on June 26, 2015. The study period included data from April 1, 2013 to March 31, 2015.

    Additional Details
    FDA Center
    CDER
    Time Period
    April 1, 2013 - March 31, 2015
    Analysis Type
    Descriptive
    Population / Cohort
    All individuals
    Data Sources
    Mini-Sentinel Distributed Dataset (MSDD)